OPICAPONE

Opicapone Overview

Opicapone (brand name Ongentys) is a prescription medicine taken by mouth. Doctors prescribe it as an add-on (adjunctive) treatment to levodopa and carbidopa for adults with Parkinson disease who are experiencing “off” episodes (times when their regular Parkinson medications wear off and symptoms return).

Key Facts Summary:

What Is Opicapone and How Does It Work?

Opicapone is a single active ingredient medicine that belongs to a class of drugs called COMT inhibitors.

Mechanism of Action

In Parkinson disease, the brain lacks a vital chemical messenger called dopamine. The main treatment for Parkinson disease is levodopa, which gets converted into dopamine inside the brain. However, enzymes in the digestive tract and bloodstream break down much of the levodopa before it can ever reach the brain. One primary enzyme responsible for breaking down levodopa in the peripheral nervous system is catechol-O-methyltransferase (COMT).

Opicapone works as a selective, reversible, high-affinity peripherally acting COMT inhibitor. By blocking the COMT enzyme, Opicapone prevents the peripheral breakdown of levodopa to 3-O-methyldopa (3-OMD). This allows a higher and more consistent amount of levodopa to cross the blood-brain barrier, prolonging its beneficial clinical effects, smoothing out plasma levodopa concentration fluctuations, and decreasing daily “off” time.

Is Opicapone FDA Approved?

Yes, Opicapone is officially approved by the United States Food and Drug Administration.

What Is Opicapone Used For?

• Add-on (adjunctive) treatment to levodopa/carbidopa in adult patients with Parkinson disease who are experiencing “off” episodes.

Before Taking Opicapone: Contraindications and Precautions

Because Opicapone increases central dopamine activity and alters catecholamine metabolism, specific clinical precautions are required.

Who Should Not Take Opicapone?

• Anyone taking non-selective monoamine oxidase (MAO) inhibitors (such as phenelzine, tranylcypromine, or isocarboxazid).
• Anyone with a catecholamine-secreting tumor (such as pheochromocytoma or paraganglioma).
• Anyone with a known severe hypersensitivity or allergic reaction to Opicapone or any of its inactive ingredients.

Opicapone, Pregnancy and Fertility

Discuss pregnancy plans with your doctor. Animal reproduction studies show potential risk to fetal development at high exposure levels, and clinical human data remains limited. It is unknown whether Opicapone passes into human breast milk. Discuss breastfeeding risks with your provider.

Tell Your Doctor Before Taking Opicapone

• Disclose any severe liver problems (hepatic impairment).
• Inform your provider if you have a history of pre-existing involuntary muscle movements (dyskinesia).
• Share if you have a history of hallucinations, psychosis, severe confusion, or intense impulse control disorders (such as pathological gambling, hypersexuality, or compulsive buying/eating).
• Provide a complete list of all active medications, particularly drugs metabolized by COMT (like isoproterenol, epinephrine, or dopamine).

Opicapone Dosage and Administration

Opicapone is an oral capsule that must be taken once daily at bedtime under strict dietary restrictions to ensure adequate bioavailability.

Standard Opicapone Dosing

• Recommended Dosage: The standard dose is 50 mg orally once daily at bedtime.
• Moderate Hepatic Impairment: Patients with moderate liver impairment (Child-Pugh Class B) require a reduced dose of 25 mg once daily at bedtime.
• Severe Hepatic Impairment: Opicapone is not recommended for patients with severe liver impairment (Child-Pugh Class C).

How Opicapone Is Administered

• Swallow the capsule whole with water. Do not open, chew, or crush the capsule.
• Take the capsule on an empty stomach at bedtime.
• Do not eat food for at least 1 hour before and at least 1 hour after taking Opicapone, as co-ingestion with food significantly decreases systemic drug absorption.

Opicapone Clinical Efficacy and Research

FDA approval of Opicapone was supported by two pivotal Phase 3 randomized, double-blind trials (BIPARK-1 and BIPARK-2) involving over 1,000 patients with Parkinson disease experiencing motor fluctuations. In these trials, adding 50 mg of Opicapone once daily to levodopa therapy demonstrated a statistically significant reduction in total daily “off” time compared to placebo. Patients experienced an average increase of over one hour of daily “on” time without troublesome dyskinesia compared to control groups.

Opicapone Side Effects and Safety Profile

Because Opicapone increases central bioavailability of levodopa, it can enhance both the therapeutic effects and dopaminergic adverse events of levodopa.

Common Opicapone Side Effects

• Involuntary muscle movements (dyskinesia).
• Constipation.
• Increased blood levels of creatine kinase.
• Orthostatic hypotension causing dizziness or lightheadedness.
• Weight loss.

Serious Opicapone Adverse Events

• Dyskinesia Exacerbation: Opicapone can cause or worsen pre-existing dyskinesia, requiring a reduction in daily levodopa dosing.
• Psychiatric and Psychotic Reactions: Hallucinations, paranoid ideation, delusion, severe confusion, or aggressive behavior.
• Impulse Control Disorders: Intense, uncontrollable urges to gamble, spend money, binge eat, or engage in compulsive sexual behaviors.
• Sudden Sleep Onset: Somnolence and falling asleep while engaging in activities of daily living (including driving).
• Orthostatic hypotension leading to syncope or severe falls.

Managing Opicapone Side Effects

If new or worsening involuntary movements develop after starting Opicapone, notify your neurologist; adjusting the underlying levodopa dose often resolves dyskinesia while retaining COMT inhibition benefits. Stand up slowly from sitting or lying positions to mitigate orthostatic blood pressure drops. If unexpected daytime sleepiness occurs, avoid driving or operating dangerous equipment.

Opicapone Drug Interactions and What to Avoid

Careful pharmacological management is necessary to avoid severe adverse reactions and systemic absorption failure.

Opicapone Drug-Drug Interactions

• Non-Selective MAO Inhibitors (Phenelzine, Tranylcypromine): Concomitant use with non-selective MAOIs is contraindicated due to the risk of severe hypertension or excessive catecholamine inhibition. Selective MAO-B inhibitors (such as rasagiline or selegiline) may generally be co-administered.
• Drugs Metabolized by COMT (Isoproterenol, Epinephrine, Norepinephrine, Dobutamine): Concomitant administration may cause increased heart rate, blood pressure fluctuations, or cardiac arrhythmias.

Opicapone, Food and Alcohol

• Strictly avoid consuming food for 1 hour before and 1 hour after taking Opicapone.
• Avoid alcohol if experiencing dizziness, orthostatic hypotension, or somnolence.

Opicapone Missed Dose, Overdose and Storage

Consistent daily dosing at bedtime maintains steady peripheral COMT inhibition and stable levodopa plasma levels.

Missed Dose of Opicapone

If a dose is missed at bedtime, skip the missed dose and take the regular 50 mg dose the following night at the scheduled bedtime. Do not take two doses at the same time to make up for a missed dose.

Opicapone Overdose and Emergency

In case of an accidental overdose, seek immediate emergency medical evaluation or contact a Poison Control Center. Manifestations of overdose align with excessive dopaminergic stimulation, including severe dyskinesia, agitation, severe hypotension, nausea, or vomiting.

How to Store Opicapone

• Store capsules at room temperature between 68°F and 77°F (20°C and 25°C).
• Keep the bottle tightly closed in a dry place to protect from moisture.
• Keep safely out of reach of children and pets.

Opicapone Patient Management and Monitoring

Regular clinical monitoring with your neurologist ensures that Parkinson motor fluctuations are managed safely and effectively.

Tests Before Starting Opicapone

• Baseline evaluation of liver function tests (ALT, AST, total bilirubin).
• Assessment of current levodopa schedule and baseline dyskinesia severity.
• Baseline screening for pre-existing impulse control disorders, hallucinations, or daytime somnolence.

Monitoring During Opicapone Treatment

• Periodic monitoring of hepatic function, particularly in patients with pre-existing liver disease.
• Routine clinical evaluation for new or worsening dyskinesia, hallucinations, or compulsive behavioral urges.
• Blood pressure monitoring, particularly orthostatic vital sign checks.

Opicapone Do’s and Don’ts

• DO take Opicapone once daily at bedtime on an empty stomach.
• DO report visual/auditory hallucinations or intense behavioral urges to your physician immediately.
• DON’T consume any food for 1 hour before or 1 hour after taking your capsule.
• DON’T drive or operate heavy machinery if experiencing daytime drowsiness or sudden sleep onset.

Frequently Asked Questions

References

• U.S. FDA prescribing information for Ongentys (Opicapone) capsules
• U.S. FDA Drugs@FDA drug approval overview (Application No. 212489)
• BIPARK-1 and BIPARK-2 Phase 3 Clinical Trial Results in Parkinson Disease
• Movement Disorder Society Guidelines on Parkinson Disease Pharmacotherapy

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.